| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Lab | Pharmaceuticals& Drugs | 1,270 |
-7.05 (-0.55%) |
Mid Cap | 32,644 | 50.3 | 16.93 | 25.4 | 2.8 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,073.1 |
-5.3 (-0.49%) |
Mid Cap | 23,242 | 50.1 | 19.92 | 21.5 | 4 | |
| Lupin | Pharmaceuticals& Drugs | 2,277.8 |
0.75 (0.03%) |
Mid Cap | 22,708 | 116.6 | 14.55 | 19.5 | 4.6 | |
| Glenmark Pharma | Pharmaceuticals& Drugs | 2,161.4 |
4.55 (0.21%) |
Mid Cap | 13,322 | 48.3 | 9.67 | 44.7 | 5.8 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,423.5 |
28.35 (2.03%) |
Mid Cap | 10,933 | 42 | 15.17 | 33.5 | 3.6 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,361.7 |
4.95 (0.21%) |
Mid Cap | 9,498 | 49.3 | 18.61 | 48.3 | 6 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,350 |
0.65 (0.01%) |
Mid Cap | 8,813 | 182.8 | 23.18 | 29.2 | 4.6 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,370.6 |
-5.4 (-0.39%) |
Mid Cap | 6,813 | 16.5 | 12.82 | 83.6 | 14.1 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,552.2 |
1.45 (0.09%) |
Mid Cap | 6,635 | 44.6 | 12.45 | 35.3 | 5 | |
| Abbott India | Pharmaceuticals& Drugs | 26,265 |
176 (0.67%) |
Mid Cap | 6,409 | 730.4 | 22.1 | 36 | 11.7 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 3,073.3 |
-5 (-0.16%) |
Mid Cap | 4,648 | 84.5 | 19.35 | 36.4 | 8.5 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 2,189.6 |
-11.6 (-0.53%) |
Mid Cap | 3,822 | 61.2 | 25.36 | 36 | 16.3 | |
| Biocon | Pharmaceuticals& Drugs | 415 |
-1.3 (-0.31%) |
Mid Cap | 2,243 | 0.2 | 8.04 | 1,813.7 | 2.5 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 768.5 |
-0.3 (-0.04%) |
Mid Cap | 1,841 | 11.9 | 27.24 | 64.9 | 13.7 |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: